With latest data, can AstraZeneca's COPD triple combo rival Glaxo's Trelegy?

AstraZeneca’s been struggling to measure up to archrival GlaxoSmithKline in the respiratory department, and the latest data on its triple-combination COPD candidate may not do much to help that situation.